India, April 8 -- Sanofi Winthrop Industrie announced that positive results from the HERCULES phase 3 study, published in The New England Journal of Medicine (NEJM), showed that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), a condition with no currently approved treatment options.
The company noted that the findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity.
The regulatory submission for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis and to slow disability accumulation independent of relapse activity in adult patients is being ...